Found 20 results
Author Title Type [ Year(Asc)]
Filters: Author is Bernstein, DI  [Clear All Filters]
2014
M. J. Mulligan, Bernstein, D. I., Winokur, P., Rupp, R., Lai, L., Anderson, E., Rouphael, N., Dickey, M., Stapleton, J. T., Edupuganti, S., Spearman, P., Kabbani, S., Ince, D., Noah, D. L., Hill, H., and Bellamy, A. R., Avian Influenza A/H7N9 Vaccine Mixed with MF59 Adjuvant at the Point-of-Use. A Randomized Clinical Trial of a Pandemic Threat Response., in ID Week 2014, Philadelphia, PA, 2014.
R. B. Belshe, Heineman, T. C., Bernstein, D. I., Bellamy, A. R., Ewell, M., van der Most, R., and Deal, C. D., Correlate of Immune Protection Against HSV-1 Genital Disease in Vaccinated Women, J Infect Dis, vol. 209, pp. 828-836, 2014.
J. M. Schulte, Bellamy, A. R., Hook, E. W., Bernstein, D. I., Levin, M. J., Leone, P. A., Sokol-Anderson, M., Ewell, M., Wolff, P. A., Heineman, T. C., and Belshe, R. B., HSV-1 and HSV-2 Seroprevalence in the United States Among Asymptomatic Women Unaware of any Herpes Simplex Virus Infection (Herpevac Trial for Women), Southern Medical Journal, vol. 107, pp. 79-84, 2014.
D. I. Bernstein, Jackson, L., Patel, S. M., Sahly, H. M., Spearman, P., Rouphael, N., Jr., T. L. Rudge, Hill, H., and Goll, J. B., Immunogenicity and Safety of Four Different Dosing Regimens of Anthrax Vaccine Adsorbed for Post-Exposure Prophylaxis for Anthrax in Adults, Vaccine, vol. 32, pp. 6284-6293, 2014.
M. J. Mulligan, Bernstein, D. I., Winokur, P., Rupp, R., Anderson, E., Rouphael, N., Dickey, M., Stapleton, J. T., Edupuganti, S., Spearman, P., Ince, D., Noah, D. L., Hill, H., and Bellamy, A. R., Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use with MF59 Adjuvant: A Randomized Clinical Trial, JAMA, vol. 312, pp. 1409-1419, 2014.
J. E. Ledgerwood, Yamschikov, G., Enama, M. E., Sarwar, U. N., Bailer, R. T., Larkin, B., Bellamy, A. R., Anderson, E. L., Bernstein, D. I., Creech, B., Keyserling, H., Spearman, P., Wright, P., and Graham, B., VRC 702: A Multicenter Phase 1 Study of Seasonal Influenza DNA Vaccine Prime Followed by the Trivalent Inactivated Vaccine (TIV) Compared to TIV-TIV in Children and Adolescents Ages 6-17 Years, in 2014 Annual Conference on Vaccine Research, Bethesda, MD, 2014.